Mergers & Acquisitions - Mergers & Acquisitions, Rare diseases

Filter

Popular Filters

1 to 25 of 36 results

Marathon Pharma sells non-strategic products to Valeant

24-02-2015

Marathon Pharmaceuticals, a privately held US biopharmaceuticals company focused on drugs for people…

Marathon PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesValeant Pharmaceuticals International

Sosei acquires Heptares Therapeutics for up to $400 million

Sosei acquires Heptares Therapeutics for up to $400 million

23-02-2015

Japanese drugmaker Sosei Group says it has acquired Heptares Therapeutics, a clinical-stage private UK-based…

BiotechnologyHeptares TherapeuticsMergers & AcquisitionsNeurologicalRare diseasesSosei

New biotech start-up OptiKira created by BioMotiv

New biotech start-up OptiKira created by BioMotiv

02-02-2015

USA-based BioMotiv, a drug development accelerator associated with The Harrington Project, the University…

BioMotivBiotechnologyDiabetesMergers & AcquisitionsOptiKiraRare diseasesResearch

Roche continues spending spree, with acquisition of French biotech firm Trophos

Roche continues spending spree, with acquisition of French biotech firm Trophos

16-01-2015

Continuing its recent spate of deal-making, Swiss pharma giant Roche has agreed to acquire Trophos, a…

BiotechnologyMergers & AcquisitionsolesoximeRare diseasesRocheSwitzerlandTrophos

GlobalData believes Shire-NPS deal to be 'robust'

GlobalData believes Shire-NPS deal to be 'robust'

15-01-2015

Ireland-headquartered drugmaker Shire’s deal to acquire NPS Pharmaceuticals is ‘robust’, according…

GattexGlobalDataMergers & AcquisitionsNatparaNPS PharmaceuticalsPharmaceuticalRare diseasesResearchShire

Shire to spend $5.2 billion to buy NPS Pharma

Shire to spend $5.2 billion to buy NPS Pharma

12-01-2015

Recently jilted Ireland-headquartered Shire says it is to acquire NPS Pharmaceuticals, confirming recent…

BiotechnologyEuropeGattexMergers & AcquisitionsNatparaNPS PharmaceuticalsRare diseasesRevestiveShire

BioMarin to acquire Prosensa for up to $840 million

BioMarin to acquire Prosensa for up to $840 million

24-11-2014

US drugmaker BioMarin Pharmaceutical has entered into a definitive agreement to purchase all of the outstanding…

BioMarin PharmaceuticaldrisapersenMergers & AcquisitionsPharmaceuticalProsensaRare diseases

UPDATE: AstraZeneca divests Myalept for $325 million

06-11-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a definitive agreement…

Aegerion PharmaceuticalsAstraZenecaMergers & AcquisitionsMyaleptPharmaceuticalRare diseases

Endo’s buy of struggling Auxilium for $2.6 billion analysed by GlobalData

12-10-2014

Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals (The Pharma Letter October 9)…

Auxilium PharmaceuticalsEndo InternationalMen's HealthMergers & AcquisitionsPharmaceuticalRare diseasesTestimTestopelXiaflex

Avalon Ventures and GlaxoSmithKline launch two new companies

23-09-2014

Avalon Ventures today announced the launch of two new companies formed through its collaboration with…

Avalon VenturesFinancialGlaxoSmithKlineHematologyMergers & AcquisitionsPharmaceuticalRare diseasesSilarus TherapeuticsThyritope Biosciences

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Riemser Pharma acquires French drugmaker Keocyt

12-05-2014

German specialty pharmaceutical company Riemser Pharma (formerly Riemser Arzneimittel) said today that…

KeocytMergers & AcquisitionsOncologyPharmaceuticalRare diseasesRiemser Pharma

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma

20-12-2013

Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

1 to 25 of 36 results

COMPANY SPOTLIGHT

Menarini

Back to top